Concepedia

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer

Haa‐Na Song, Ki Sun Jung, Kwai Han Yoo, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn,

Journal of Thoracic Oncology · 2015 · 109 citations · 4 references

DOIFull text

Open access

Concepts

References

4

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

, , +16

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

David Planchard, Yohann Loriot, Fabrice André et al. · Annals of Oncology · 2015 · 313 citations

, , +14

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Catherine A. Eberlein, Daniel Stetson, Aleksandra Markovets et al. · Cancer Research · 2015 · 300 citations · Full text

, , +17

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Keunchil Park, Jong-Seok Lee, Ki Hyeong Lee et al. · Journal of Clinical Oncology · 2015 · 50 citations

, , +17